Chemotherapy for Ovarian Cancer: A Comprehensive Guide to Your Treatment Journey

A diagnosis of ovarian cancer can feel overwhelming, and when your doctor recommends chemotherapy, you might find yourself facing a whirlwind of emotions and questions. But knowledge is a powerful ally in this journey. Let’s explore chemotherapy for ovarian cancer together, providing you with the information you need to approach your treatment with confidence and understanding.

Chemotherapy for ovarian cancer is often the primary treatment following surgery. It acts as a systemic approach to eliminate any remaining cancer cells throughout the body. Before we delve into the details, let’s outline the key aspects of this crucial treatment.

Chemotherapy for Borderline Tumors and Low-Grade Serous Ovarian Cancer

While chemotherapy is a standard treatment for many types of ovarian cancer, its effectiveness varies for borderline ovarian cancer (also called borderline ovarian tumors, or BOT) and low-grade serous ovarian cancer (LGSOC).

Chemotherapy is generally not recommended for borderline ovarian tumors. These tumors, also known as tumors of low malignant potential, typically respond well to surgical removal alone. The slow-growing nature of these tumors makes them less responsive to chemotherapy, which targets rapidly dividing cells.

As for LGSOC, the effectiveness of traditional chemotherapy is significantly limited compared to its impact on high-grade serous ovarian cancer. Recent research and clinical experience have shown that LGSOC tends to be particularly resistant to standard chemotherapy regimens.

It’s important to note that while chemotherapy’s effectiveness is limited in LGSOC compared to high-grade serous ovarian cancer, platinum-based chemotherapy remains the standard of care for LGSOC patients. This means it is typically the first-line treatment covered by insurance companies. 

However, emerging evidence from clinical trials and patient outcomes has led many medical professionals to also consider alternative approaches. Current treatment strategies increasingly incorporate additional options such as hormonal therapies, targeted therapies like MEK inhibitors, and innovative clinical trials, often in combination with or following standard chemotherapy protocols.

As our understanding of LGSOC evolves, patients need to engage in thorough discussions with their oncologists about their specific diagnosis and treatment options. Your ovarian cancer doctor and medical team can offer personalized recommendations based on the latest research, but remember: as a patient, you’re an essential part of the decision-making process. 

Don’t shy away from asking questions, seeking second opinions, or voicing your concerns. Your informed input is crucial in developing a treatment plan that aligns with both current medical best practices and your personal health goals.

Types of Chemotherapy Drugs for Ovarian Cancer

Chemotherapy drugs for ovarian cancer are carefully selected based on your specific diagnosis, cancer stage, and overall health. Your oncologist will create a personalized ovarian cancer treatment plan, often combining different drugs for maximum effectiveness. Here’s a look at the most common chemotherapy drugs used in ovarian cancer treatment:

Platinum-based Drugs

Platinum-based drugs are a cornerstone of ovarian cancer treatment due to their effectiveness against cancer cells. How they work: Think of DNA as an instruction manual that tells cells how to grow and divide. Platinum-based drugs work by binding to this DNA instruction manual in cancer cells. When the heavy metal platinum attaches to the DNA, it damages these instructions, preventing cancer cells from growing and dividing properly, which leads to their death.

• Carboplatin: This drug is often the first choice due to its effectiveness and manageable side effect profile.
• Cisplatin: While an older platinum drug, cisplatin is still used in certain cases.

Taxanes 

Taxanes are another crucial class of drugs in ovarian cancer treatment. These drugs were originally derived from the bark of the Pacific yew tree but are now synthesized in laboratories.

How they work: Taxanes interfere with cell division by over-stabilizing microtubules, which are essential structures that need to naturally assemble and disassemble during cell division. 

By forcing these microtubules to stay assembled when they should be breaking down, taxanes freeze the cell’s division machinery in place. This prevents chromosomes from separating properly during cell division, ultimately stopping cancer cells from being able to divide and spread.

• Paclitaxel (Taxol): This is the most commonly used taxane for ovarian cancer.
• Docetaxel (Taxotere): Docetaxel is sometimes used as an alternative to paclitaxel. 
• Albumin-bound paclitaxel (Abraxane): This newer formulation may have fewer side effects.

Anthracyclines 

Anthracyclines are effective against a wide range of cancers, including ovarian cancer. These drugs work in several ways: they insert themselves between the building blocks of DNA, disrupting its normal structure and function. 

They also block an important enzyme called topoisomerase II, which normally helps unwind DNA so it can be copied when cells divide. By preventing DNA from being unwound and copied, anthracyclines stop cancer cells from multiplying. 

Additionally, these drugs can generate molecules called free radicals, which cause further damage to cancer cells by harming their DNA, proteins, and cell membranes. This multi-targeted approach makes anthracyclines particularly effective in fighting cancer cells through different pathways.

• Doxorubicin: This drug is often used in cases of recurrent ovarian cancer. 
• Pegylated liposomal doxorubicin (Doxil): This formulation may have fewer side effects compared to standard doxorubicin.

Antimetabolites 

Antimetabolites work by interfering with DNA and RNA production in cancer cells. They do this by mimicking the building blocks of these genetic materials, disrupting the cell’s ability to grow and divide.

• Gemcitabine: This drug is often used in combination therapies or for recurrent cancer. 
• Capecitabine: This is an oral drug sometimes used in advanced cases.

Other Agents 

Several other drugs don’t fit neatly into the above categories but play important roles in ovarian cancer treatment.

• Topotecan: This drug can be particularly useful in recurrent cases of ovarian cancer.
• Etoposide: Etoposide is sometimes used in combination therapies.
• Cyclophosphamide: This is an alkylating agent that damages DNA in cancer cells.
• Bevacizumab: This is a monoclonal antibody that binds to VEGF which promotes the formation of blood vessels. VEGF is over-expressed in tumors so that they can form their own blood supply and metastasize.

These drugs have varied mechanisms of action. Topotecan and etoposide interfere with DNA replication, while cyclophosphamide directly damages DNA, preventing cancer cells from dividing.

Your oncologist may use a combination of these drugs, typically pairing a platinum-based drug with a taxane as first-line treatment. This approach, known as combination chemotherapy, aims to attack cancer cells through multiple mechanisms, increasing the chances of treatment success.

Each type of drug brings unique benefits to ovarian cancer treatment. Understanding how they work can help you appreciate the science behind your treatment plan. Your oncologist is always available to answer any questions you might have about your specific treatment regimen.

Emerging Therapies in Clinical Trials

While traditional chemotherapy remains a cornerstone of ovarian cancer treatment, exciting developments are happening in research laboratories and ovarian cancer clinical trials across the country. These emerging therapies offer hope, particularly for patients with treatment-resistant cancer or those seeking alternatives to standard protocols.

CAR-T Cell Therapy: A New Frontier

One of the most promising areas of research involves CAR-T cell therapy, where a patient’s own immune cells are genetically modified to better recognize and attack cancer cells. Multiple clinical trials are currently underway for ovarian cancer, targeting specific proteins found on cancer cell surfaces.

Early results show encouraging signs. In some ongoing trials, patients have surpassed their expected survival times, with one patient remaining alive 28 months post-treatment in a recent study. These therapies target various markers including TAG72, FSHR (follicle-stimulating hormone receptor), mesothelin, and others that are commonly found on ovarian cancer cells.

Why This Matters for Our Mission

At Not These Ovaries, we’re particularly excited about research that could benefit patients with low-grade serous ovarian cancer and borderline ovarian tumors. These subtypes have been historically underresearched, which is exactly why 100% of donations to our organization go directly to funding trials that could change outcomes for younger women facing these diagnoses.

How to Access Clinical Trials

If you’re interested in exploring clinical trial options, discuss this with your gynecologic oncologist. They can help determine if you’re eligible for any ongoing studies. You can also search for trials at ClinicalTrials.gov or learn more about the benefits of ovarian cancer clinical trials.

How Many Times Can You Have Chemotherapy for Ovarian Cancer?

The number of chemotherapy cycles you’ll undergo depends on several factors:

• Your cancer’s stage and type
• Your body’s response to treatment
• The specific chemotherapy regimen chosen

Typically, women diagnosed with ovarian cancer receive about 6 cycles of chemotherapy, usually administered every 3 weeks. However, your treatment plan may differ. Some patients require fewer cycles, while others may need more or ongoing maintenance therapy.

To facilitate the administration of chemotherapy, a portacath (also known as a port) is often used. A portacath is a small, implantable device inserted under the skin, typically in the chest area, through a minor outpatient surgical procedure. The port is connected to a catheter that leads to a large vein, allowing for easier access to the bloodstream during chemotherapy sessions. 

The portacath remains in place for the duration of the chemotherapy cycles and can be used for extended periods if additional treatment is necessary.

It’s important to note that if your cancer recurs (comes back after a period of remission or no detectable cancer), additional rounds of chemotherapy may be necessary. Your previous responses to treatment will help guide future decisions, allowing your medical team to refine your care plan continually.

How Effective is Chemotherapy for Ovarian Cancer?

The effectiveness of chemotherapy for ovarian cancer can vary significantly between individuals. Here’s what you should know:

• For early-stage ovarian cancer, chemotherapy can significantly improve the chances of long-term remission after surgery.
• In advanced cases, chemotherapy can shrink tumors and extend life, sometimes for years.
• Even when a cure isn’t possible, chemotherapy can often control the cancer, improving quality of life and extending survival.

Factors influencing effectiveness include:

• The specific type and stage of ovarian cancer
• Your overall health and fitness
• Genetic factors, such as BRCA mutations

While chemotherapy is a powerful tool in fighting ovarian cancer, it’s essential to have realistic expectations and open communication with your ovarian cancer doctor and healthcare team about your treatment goals and outcomes.

Staying Current with Evolving Guidelines

Treatment recommendations for ovarian cancer continue to evolve as new research emerges. The National Comprehensive Cancer Network (NCCN) updated their guidelines in 2024, refining recommendations for maintenance therapies and treatment sequencing. These updates reflect our growing understanding of how different ovarian cancer subtypes respond to treatment.

For patients with borderline ovarian tumors, the approach remains quite different from invasive cancers. These tumors typically don’t require chemotherapy at all, since they respond well to surgical removal alone. However, for those facing low-grade serous ovarian cancer, the treatment landscape is more complex, with limited options specifically proven effective for this subtype.

This is precisely why research funding is so critical. While we’ve made tremendous strides in treating high-grade serous ovarian cancer, patients with rarer subtypes often find themselves with fewer proven options. Every dollar donated to organizations like Not These Ovaries directly funds research that could change this reality.

Before Starting Chemotherapy: What You Need to Know

Preparing for chemotherapy can help you feel more in control of your treatment journey. Here’s a pre-treatment checklist to consider:

• Complete health assessment: Your doctor will conduct thorough tests to ensure your body is ready for treatment.
• Discuss fertility preservation:  If having children is in your future plans, talk to your doctor about potential options. However, it’s important to understand that fertility preservation might not be possible for all patients. The location of tumors on the ovaries or the necessity of a bilateral oophorectomy (removal of both ovaries) during surgery can limit these options. Your oncologist can provide a realistic assessment based on your specific situation.
• Prepare your home: Stock up on essentials and create a comfortable environment for your recovery periods.
• Build your support network: Identify family, friends, or support groups who can assist you during treatment.
• Ask questions: Don’t hesitate to seek clarification on any aspect of your treatment plan. (See this list of essential ovarian cancer questions to ask.)
• Understand potential side effects: Familiarize yourself with common ovarian cancer chemotherapy side effects and take time to discuss management strategies with your healthcare team.
• Address practical matters: Sort out insurance, work arrangements, and any necessary legal documents.

Remember, starting chemotherapy is about adapting to a new normal. With proper preparation and support, you can face this challenge with resilience and determination.

Targeted Therapies for Ovarian Cancer

Targeted therapies represent a cutting-edge approach to ovarian cancer treatment. These innovative drugs are designed to zero in on specific molecules or pathways crucial for cancer cell growth and survival. By focusing on these specific targets, these therapies aim to effectively combat cancer while reducing harm to healthy cells.

Three main types of targeted therapies are commonly used in ovarian cancer treatment:

Anti-angiogenic agents: These drugs, like bevacizumab (Avastin), disrupt the formation of new blood vessels that tumors need to grow and spread. By cutting off the tumor’s blood supply, these agents can help slow cancer progression. 

They’re often used alongside traditional chemotherapy to enhance treatment effectiveness and delay disease advancement in advanced stages of ovarian cancer.

PARP inhibitors: PARP inhibitors, including olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula), take advantage of a vulnerability in certain ovarian cancer cells. They’re particularly effective against cancers with mutations in the BRCA1 or BRCA2 genes, or those with homologous recombination deficiency (HRD). 

These genetic changes impair the cancer cells’ ability to repair DNA damage, making them more susceptible to PARP inhibitors. These drugs are often used as maintenance therapy following chemotherapy to help prevent or delay cancer recurrence.

Aromatase inhibitors: This class of drugs plays a crucial role in treating estrogen receptor-positive ovarian cancers, which account for approximately 99% of cases. Aromatase inhibitors work by blocking the production of estrogen in the body. 

By reducing estrogen levels, these drugs can slow or stop the growth of estrogen-dependent cancer cells. Common aromatase inhibitors include letrozole, anastrozole, and exemestane. They’re particularly important in the treatment of specific subtypes of ovarian cancer, such as low-grade serous ovarian cancer (LGSOC), where hormonal factors play a significant role in tumor growth.

Before recommending targeted therapy, your oncology team may conduct genetic testing on your cancer cells. This helps identify specific mutations that these drugs can target, allowing for a more personalized treatment approach. This tailored strategy aims to improve treatment outcomes while minimizing potential side effects.

The field of targeted therapy is rapidly evolving, with ongoing research exploring new targets and treatment combinations. Your oncologist can provide the most up-to-date information on how these therapies might fit into your overall treatment plan, taking into account your specific type of ovarian cancer and its molecular characteristics.

Navigating Your Chemotherapy Journey

Chemotherapy for ovarian cancer is a challenging but often crucial part of treatment. With the correct information, support, and mindset, it’s a challenge you can face with strength and dignity. But remember: you’re not just a patient in this process. You’re an essential partner in your care.

Here are some key strategies to help you through:

Ask the Right Questions: Don’t hesitate to dig deep with your oncology team. Some essential questions include:

• Are there any newer treatments I should know about, including clinical trials?
• How will we monitor if this treatment is working?
• What are my options if this treatment stops working?
• Should I seek a second opinion, particularly at a comprehensive cancer center?

You can find more essential ovarian cancer questions to guide these conversations.

Stay Informed About Your Options: The treatment landscape is evolving rapidly. What wasn’t available six months ago might be an option today. This includes new targeted therapies, PARP inhibitors, and emerging treatments in clinical trials.

Build Your Medical Team: Ensure you’re working with specialists who understand ovarian cancer inside and out. A gynecologic oncologist should be leading your care, as research consistently shows better outcomes when ovarian cancer patients are treated by these specialists.

Balance Rest and Gentle Activity: Listen to your body, but gentle movement when you feel up to it can help manage treatment side effects and maintain your strength.

Nutrition Matters, But Don’t Stress: Eat what you can and when you can. Any calories are good calories during chemo. Focus on staying hydrated and getting nutrition however works for your body. If you’re struggling to eat for several days, alert your medical team immediately.

Lean on Your Support Network: They’re your cheerleaders in this fight. Don’t be afraid to ask for help with practical things like meals, transportation, or childcare.

Celebrate Every Milestone: Each completed cycle, each scan showing progress, each day you feel a little stronger: these victories matter.

Plan for After Treatment: Recovery takes time, both physically and emotionally. Many women find that joining ovarian cancer support groups or speaking with a therapist can be invaluable in processing their experience and moving forward.

The Bigger Picture: Why Your Journey Matters

Your experience — the challenges you face, the treatments you try, the outcomes you achieve — all contribute to the knowledge that helps future patients. When you participate in clinical trials, when you advocate for better care, when you support research funding, you’re not just fighting for yourself. You’re fighting for every woman who will face this diagnosis after you.

At Not These Ovaries, we believe that action and understanding will save lives. That’s why we fund research into the rare subtypes of ovarian cancer. Because every woman deserves treatments that work for her specific diagnosis.

With knowledge, support, and the right medical team, you’re equipped to face chemotherapy head-on. Your resilience is powerful. Your voice matters. And together, we’re working towards a future where ovarian cancer is a challenge of the past.